Thursday Program

 

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Hall C1

MYELOPROLIFERATIVE DISORDERS
Chair: H Pahl (University Hospital Freiburg, Freiburg, Germany)

NEW INSIGHTS INTO LEUKOCYTES AND THROMBOSIS IN
MYELOPROLIFERATIVE DISORDERS
A Falanga (Ospedali Riuniti Bergamo, Bergamo, Italy)

MYELOFIBROSIS IN THE GATA-1 LO MOUSE MODEL
A Migliaccio (Sambarraele, Honza, Italy)

CONCORDANCE OF ASSAYS DESIGNED FOR THE QUANTITATION
OF JAK2: A MULTI-CENTRE STUDY
S Hermouet (Laboratoire d'Hematologie, CHU Nantes, Nantes, France)

PROTEOMICS IN MYELOPROLIFERATIVE DISORDERS
P Mossuz (University Hospital of Grenoble, Grenoble, France)

HETEROGENEITY WITHIN JAK2 V617F POLYCYTHEMIA VERA:
A FUNCTIONAL APPROACH TO SEARCH FOR ADDITIONAL
MOLECULAR DEFECTS
F Delhommeau (Hôpital Saint Antoine, Paris, France)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Hall C3

EUROPEAN STUDY GROUP ON MINIMAL RESIDUAL DISEASE
DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA
Chair: T Raff (University Hospital Schleswig - Holstein, Campus Kiel, Kiel, Germany)

AIMS OF EUROPEAN STUDY GROUP ON MINIMAL RESIDUAL
DISEASE DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA
E Macintyre (Hopital Necker/Enfants Malades, Paris, France)

MINIMAL RESIDUAL DISEASE DIAGNOSTICS IN B-CELL LYMPHOMAS:
TECHNICAL ASPECTS AND CLINICAL RELEVANCE
E Pott (University Hospital Schleswig-Holstein, Kiel, Germany)

MONITORING OF PH+ ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
H Pfeifer (Universitätsklinikum Frankfurt, Frankfurt, Germany)

RELEVANCE OF STANDARDIZATION AND QUALITY CONTROL
IN MINIMAL RESIDUAL DISEASE DIAGNOSTICS
T Raff (University Hospital Schleswig - Holstein, Campus Kiel,
Kiel, Germany)

ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS-AIEOP-BFM 2000:
MINIMAL RESIDUAL DISEASE BASED RISK GROUP STRATIFICATION IN
MORE THAN 4000 PATIENTS WITH CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS: LOGISTICS WITHIN AND BETWEEN MINIMAL
RESIDUAL DISEASE-LABS AND TRIAL CENTERS
A Schrauder (Universitätsklinikum Schleswig-Holstein, Campus Kiel,
Kiel, Germany)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Hall C5

EUROFLOW
Chair: J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

REQUIRED INNOVATIONS IN DIAGNOSTIC FLOW CYTOMETRY:
CHALLENGES FOR EUROFLOW
J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

IMMUNOBEAD TECHNOLOGY FOR DETECTION OF FUSION PROTEINS
E Dekking (Erasmus Medical Center, Rotterdam, The Netherlands)

ADVANCES IN THE INTEGRATION OF LIST MODE DATA FROM
MULTI-TUBE IMMUNOSTAINING PROTOCOLS
A Orfao (University of Salamanca, Salamanca, Spain)

DEVELOPMENT OF 8-COLOR IMMUNOSTAINING PROTOCOLS
IN HEMATO ONCOLOGY: ACUTE LYMPHOBLASTIC LEUKEMIA AT
DIAGNOSIS AS EXAMPLE
L Lhermitte (Hôpital Necker-Enfants Malades, Paris, France)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B1

CHRONIC MYELOID LEUKEMIA
Chair: J Goldman (Hammersmith Hospital, London, United Kingdom)

WHAT CAN ARRAY COMPARATIVE GENOMIC HYBRIDIZATION
TELL US ABOUT CML
E Nacheva (Royal Free & UCL Medical School, London, United
Kingdom)

GENE EXPRESSION PROFILING IN CHRONIC MYELOID LEUKEMIA -
WHERE WILL IT LEAD?
D Wolf (Universitätsklinik, Innsbruck, Austria)

KINASE DOMAIN MUTATIONS - HOW REALLY IMPORTANT ARE THEY?
S Soverini (Institute of Hematology and Medical Oncology "Seràgnoli",
Bologna, Italy)

DIFFICULT CLINICAL DECISIONS IN 2008
P Rousselot (Hôpital André Mignot, Paris, France)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B2

PHARMACOKINETIC, PHARMACOGENETIC & PHARMACODYNAMICS
Chair: M Hassan (Karolinska Institute of medicine, Stockholm, Sweden)

CIRCADIAN CLOCK CONTROL OF CELL CYCLE AND
ANTICANCER DRUG PHARMACOLOGY
F Albertioni (Karolinska Hospital, Stockholm, Sweden)

PHARMACOKINETIC VARIABILITY OF ALKYLATING AGENTS.
IS THERE PHARMACODYNAMIC SIGNIFICANCE?
R Jones (M.D. Anderson Cancer Center, Houston, USA)

COMPARATIVE STUDY ON HEMATOPOIETIC TOXICITY OF CISPLATIN
AND NON-TRADITIONAL ANTITUMOR AGENTS IN EHRLICH ASCITES
CARCINOMA
M El Azab (Suez Canal University, Faculty of Pharmacy, Ismailia, Egypt)

USING SYSTEMIC EXPOSURE TO OPTIMIZE THE SAFETY OF
PRETRANSPLANT THERAPY FOR MALIGNANT DISEASE
B Andersson (M.D. Andersson Cancer Centre, Houston, USA)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B3

MULTIPLE MYELOMA
Chair: P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)

THE CANCER STEM CELL CONCEPT IN MULTIPLE MYELOMA
H Johnsen (Aalborg Hospital, Aalborg, Denmark)

THE B-CELL HIERARCHY IN MALIGNANCY
M Perez Andres (Universidad de Salamanca, Salamanca, Spain)

TRACKING THE MYELOMA COMPARTMENT
S Sahota (University of Southampton, Southampton, United Kingdom)

IN SEARCH OF GENETIC PROFILE PREDICTING CHEMORESISTANCE
P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)

THE 5TMM MYELOMA MOUSE MODEL
K Vanderkerken (Vrije Universiteit Brussel, Brussel, Belgium)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B4

MYELODYSPLASTIC SYNDROMES
Chair: T de Witte (Radboud University Nijmegen Medical Center,
Nijmegen, The Netherlands)

IMMUNOPHENOTYPING IN DIAGNOSTIC GUIDELINES IN
MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA:
REPORT FROM FLOWCYTOMETRY WORKSHOP MARCH 27-28, 2008
A van de Loosdrecht (VU Medical Center, Amsterdam, The Netherlands)

IMMUNOLOGICAL PATHWAYS IN THE PATHOBIOLOGY OF
MYELODYSPLASTIC SYNDROMES
G Mufti (King’s College London, London, United Kingdom)

IDENTIFICATION OF (NEW) GENETIC LESIONS IN MYELODYSPLASTIC
SYNDROMES USING HIGH RESOLUTION SNP-ARRAYS
J Jansen (Radboud University Nijmegen Medical Center, Nijmegen,
The Netherlands)

DEVELOPMENT OF A MOUSE MODEL OF MYELODYSPLASTIC
SYNDROME PROGRESSION
R Padua (Institute Universitaire d’Hematologie, Paris, France)

WEB-BASED TRAINING PROGRAM FOR THERAPEUTIC GUIDELINES
L Malcovati (University of Pavia, Pavia, Italy)

LENALINOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
E Hellström-Lindberg (Karolinska Institute, Stockholm, Sweden)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B5

GRANULOCYTE AND MONOCYTE DISORDERS
Chair: H Papadaki (University of Crete, Heraklion, Greece)

CLINICAL AND LABORATORY DIAGNOSIS OF CHRONIC
NEUTROPENIC STATES
J Palmblad (Karolinska Institute, Stockholm, Sweden)

NEUTROPHIL GRANULES: A LIBRARY OF INNATE IMMUNITY
PROTEINS
N Borregaard (Rigshospitalet, Copenhagen, Denmark)

SEVERE CHRONIC NEUTROPENIA: NEW GENES OFFER NEW
TOOLS FOR THE DIFFERENTIAL DIAGNOSIS
K Welte (Medizinische Hochschule Hannover, Hannover, Germany)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B6

QUALITY OF LIFE AND SYMPTOMS
Chair: C Cleeland (M.D. Anderson Cancer Center, Houston, USA)

REGULATORY IMPACT OF PATIENT REPORTED OUTCOMES (PROS)
IN CLINICAL TRIALS IN HEMATOLOGIC MALIGNANCIES
C Cleeland (M.D. Anderson Cancer Center, Houston, USA)

PROGNOSTIC SIGNIFICANCE AND LONGITUDINAL ASSESSMENT OF
PATIENT-REPORTED QUALITY OF LIFE AND SYMPTOMS IN HIGH-RISK
MYELODYSPLASTIC SYNDROMES. A LARGE-SCALE INTERNATIONAL,
OBSERVATIONAL STUDY
F Efficace (Mediterranean Institute of Hematology, Rome, Italy)

RATIONALE OF SYMPTOM ASSESSMENT IN LYMPHOMA PATIENTS
T Ionova (Multinational Center for Quality of Life, St. Petersburg, Russia)

MECHANISMS OF TREATMENT-RELATED SYMTPOMS IN
TRANSPLANTATION
X Wang (M.D. Anderson Cancer Centre, Houston, USA)

PRO IN OUTCOME ASSESSMENT: PROPER APPLICATIONS IN
CLINICAL HEMATOLOGY
A Novik (Pipoduv National Medical Surgical Center, Moscow, Russia)

MEASURING THE SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS
HOST DISEASE
L Williams, (M.D Anderson Cancer Center, Houston, USA)

---

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Room B7

THROMBOCYTOPENIAS
Chair: B Godeau (CHU Henri Mondor, Creteil, France)

"TERMINOLOGY AND DEFINITIONS IN IMMUNE THROMBOCYTOPENIC
PURPURA". A FEEDBACK AFTER THE CONFERENCE OF VICENZA
F Rodeghiero (San Bortolo Hospital, Vicenza, Italy)                         

MECHANISMS OF ACTION OF RITUXIMAB IN IMMUNE
THROMBOCYTOPENIC PURPURA: WHAT DO WE KNOW ?
R Stasi (Ospedale Regina Apostolorum, Albano Laziale, Italy)

TPO-R AGONIST: UPDATE ON CLINICAL TRIALS
J Bussel (Weill-Cornell Medical College, New York, USA)

IMMUNE THROMBOCYTOPENIC PURPURA IN THE ELDERLY
M Michel (Hemi Mondor University Hospital, Creteil, France)